(Q40165519)

18 September 2017

title

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge (English)

1 reference

18 September 2017

1 reference

10

Geert Leroux-Roels

0 references

Philip Meuleman

object named as

Philip Meuleman

13

0 references

Thomas F Baumert

11

object named as

Thomas F Baumert

1 reference

18 September 2017

9

Jane A McKeating

1 reference

18 September 2017

12

Arvind H Patel

1 reference

18 September 2017

2

Samira Fafi-Kremer

1 reference

18 September 2017

7

Lieven Verhoye

1 reference

18 September 2017

1

Isabelle Desombere

1 reference

18 September 2017

5

Ali Farhoudi

1 reference

18 September 2017

4

Patrick Pessaux

1 reference

18 September 2017

Freya Van Houtte

3

1 reference

18 September 2017

Laura Heydmann

6

1 reference

18 September 2017

Sarah Cole

8

1 reference

18 September 2017

language of work or name

English

0 references

publication date

28 December 2015

1 reference

18 September 2017

1 reference

18 September 2017

volume

63

1 reference

18 September 2017

issue

4

1 reference

18 September 2017

page(s)

1120-1134

1 reference

Global distribution and prevalence of hepatitis C virus genotypes

18 September 2017

cites work

1 reference

Curing chronic hepatitis C--the arc of a medical triumph

21 January 2018

1 reference

A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing.

21 January 2018

1 reference

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study

21 January 2018

1 reference

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

HCV animal models and liver disease

21 January 2018

1 reference

Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo

21 January 2018

1 reference

A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo

21 January 2018

1 reference

Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.

21 January 2018

1 reference

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents

21 January 2018

1 reference

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

21 January 2018

1 reference

Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors

21 January 2018

1 reference

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation

21 January 2018

1 reference

Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain

21 January 2018

1 reference

The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry

21 January 2018

1 reference

In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus

21 January 2018

1 reference

Griffithsin has antiviral activity against hepatitis C virus

21 January 2018

1 reference

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry

21 January 2018

1 reference

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

21 January 2018

1 reference

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

21 January 2018

1 reference

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

21 January 2018

1 reference

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study

21 January 2018

1 reference

Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity

21 January 2018

1 reference

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus

21 January 2018

1 reference

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein

21 January 2018

1 reference

Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus

21 January 2018

1 reference

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

21 January 2018

1 reference

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate

21 January 2018

1 reference

Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees

21 January 2018

1 reference

An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission

21 January 2018

1 reference

Broadly neutralizing antibodies abrogate established hepatitis C virus infection

21 January 2018

1 reference

Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.

21 January 2018

1 reference

Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

21 January 2018

1 reference

Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.

21 January 2018

1 reference

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

21 January 2018

1 reference

Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody

21 January 2018

1 reference

Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

21 January 2018

1 reference

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

21 January 2018

1 reference

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies

21 January 2018

1 reference

Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo

21 January 2018

1 reference

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation

21 January 2018

1 reference

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera

21 January 2018

1 reference

A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice

21 January 2018

1 reference

Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins

21 January 2018

1 reference

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant

21 January 2018

1 reference

Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity

21 January 2018

1 reference

Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.

21 January 2018

1 reference

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

21 January 2018

1 reference

Hepatitis C virus evasion mechanisms from neutralizing antibodies

21 January 2018

1 reference

Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1

21 January 2018

1 reference

Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33

21 January 2018

1 reference

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies

21 January 2018

1 reference

Blocking HCV entry as potential antiviral therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.28428

1 reference

18 September 2017

1 reference